frequency relative to that observed in the follicular phase of Vancouver Hospital and Health Sciences Centre, 805 West 12th the normal menstrual cycle (Burger et al., 1985; Waldstreicher Avenue,Vancouver, BC, Canada V5Z 1M9 et al., 1988) . The latter, however, has not been uniformly reported by all investigators (Kazer et al., 1987; Venturoli In polycystic ovary syndrome (PCOS), increased luteinizing et al., 1988) . While gonadotrophin-releasing hormone (GnRH) hormone (LH) pulse frequency has been attributed to pulsatile release cannot be assessed in vivo from the hypoeither the hypothalamic gonadotrophin-releasing hormone physeal portal circulation in humans, it is generally recognized (GnRH) pulse generator or ovarian oestrogen feedback. To that peripheral LH pulses correlate directly with those of address this issue, a detailed examination of pulsatile LH hypothalamic gonadotrophin-releasing hormone (Clarke and secretion was undertaken during recovery from GnRH Cummins, 1982; Levine and Ramirez, 1982) . Further support agonist (GnRHa) suppression. Each of six women with for increased GnRH pulse frequency is the recent observation PCOS and six normal ovulatory women received daily of a simultaneous rise in α-subunit pulsatile secretion in GnRHa treatment for 14 weeks. Frequent blood samples addition to LH (Berga et al., 1993) . Whether this increased were collected and assayed for gonadotrophins, androgens pulse frequency reflects intrinsic hyperactivity of the hypothaland oestrogens before, during and up to 4 weeks after amic GnRH pulse generator or a feedback effect secondary to treatment. Women with PCOS had higher basal LH pulse altered concentrations of circulating hormones is unknown. frequency and amplitude and increased serum concentraPreviously, we and others have demonstrated that in patients tions of LH, androstenedione, testosterone and oestrone with PCOS, resumption of gonadotrophin secretion following than controls. After 3 months of GnRHa treatment, all long-term GnRH agonist (GnRHa) suppression is marked by these parameters were suppressed with no differences an initial rise of serum follicle-stimulating hormone (FSH) observed between the two groups. One week after cessation and a subsequent gradual increase of LH which appeared to of GnRHa, LH pulse frequency promptly returned to prebe commensurate with the return of ovarian oestrogen secretion treatment range with no between-group differences noted, (Cologero et al., 1987; deZiegler et al., 1989) . This sequence whereas LH pulse amplitude, serum gonadotrophins and of gonadotrophin recovery was similar to that observed in ovarian steroids remained maximally suppressed and women with hypothalamic amenorrhoea receiving pulsatile equivalent in the two groups. Subsequent LH pulse fre- GnRH (Marshall and Kelch, 1979) . The current study was quency remained constant while LH pulse amplitude and conducted to determine whether in PCOS the resumption of circulating concentrations gradually increased in parallel gonadotrophin secretion, in particular LH pulsatile release, with a return of serum oestrogen to pre-treatment values.
was primarily a result of endogenous GnRH activity or an Despite comparable resumption of LH secretion in the two effect of ovarian steroid feedback. An understanding of the groups, corresponding androgen concentrations in women underlying mechanism(s) involved might provide an insight with PCOS were greater than those of normal ovulatory into the role of the GnRH pulse generator in the aetiology of women. Thus, the immediate restoration of LH pulse this disorder. frequency after discontinuing GnRHa treatment is largely independent of ovarian oestrogen production and reflects Materials and methods primacy of the GnRH pulse generator in determining basal LH pulse frequency. Equivalent LH pulse frequency rates described criteria (Adams et al., 1986; Ardaens et al., 1991 et al., 1985) . In contrast, only one normal ovulatory Pulse detection woman was 20% overweight.
LH peaks were objectively identified from the hormone series using the 'cluster analysis' algorithm (Veldhuis and Johnson, 1986) . To Study design determine the precision of LH measurements for the programme, the Informed consent was obtained from all subjects. The study was three variance models of linear, quadratic and power function were approved by the Human Subjects Review Committee of the University compared using at least 720 (360 duplicate) samples from each of of California, Davis. Each of six women with PCOS and six normal the seven LH radioimmunoassays. The power function B 1 x B 2 uniovulatory women received the GnRHa [(imBzl)GnRHa 6 , Pro 9 -NEt]-formly gave the least fitted variance and was the model selected for GnRH, daily for 14 weeks at a dose of 2 µg/kg subcutaneously. Each within-assay errors. In the analysis, the following parameters were subject underwent 10 min blood sampling for a 10 h period before chosen: cluster size for peak ϭ 1, nadir ϭ 2; t statistics for both up GnRHa treatment, at 12 weeks during treatment and at 1, 2 and 4 and down strokes ϭ 2 and peak size ϭ 1. The pulsar algorithm weeks after discontinuing treatment. Pre-treatment blood sampling (Merriam and Wachter, 1982) was also used to assess whether study was performed on cycle day 2 in normal controls. Women with PCOS results were affected by the choice of a particular pulse detection had not been on hormone treatment for at least 3 months prior to the programme. It was set to a type 1 error rate of 5% by entering the study. One subject with PCOS withdrew from the study 12 weeks appropriate set of G values as per algorithm. into the treatment for social reasons. GnRHa administration was Statistical analysis extended from 12 to 14 weeks to provide 2 extra weeks so that frequent blood sampling from study subjects could be safely resumed
The design of the study allowed simultaneous comparison of within-1, 2 and 4 weeks after discontinuing treatment.
and between-group changes during and after GnRHa treatment using two-factor analysis of variance (Winer, 1971) , with repeated measures Hormone assay on one factor (i.e. the five selected periods of observation). Withingroup comparisons among the five selected periods were further Serum concentrations of LH, FSH, androstenedione, testosterone and oestrone were measured by conventional radioimmunoassay as characterized using one-factor analysis of variance with repeated measures. A-priori comparison, if appropriate, was made as well as previously reported (Yen et al., 1970a; Yen et al., 1972; DeVane et al., 1975; Anderson et al., 1976) . Serum oestradiol was measured post-hoc pairwise comparison using the Scheffé F test or LSD (least significant difference) test. Between-group comparison at each by an extraction-method kit from Pentax, Santa Monica, CA, USA. Similarly, progesterone and dehydroepiandrosterone sulphate were corresponding period was also analysed by two-sample, unpaired Student's t-test. Since normality of data was not assumed, betweendetermined by radioimmunoassay kits from Diagnostic Products Corporation, Los Angeles, CA, USA. Steroid hormones were assayed group comparison was re-analysed using the non-parametric, Wilcoxon rank sum test, which made no difference to the findings. in serum pooled from blood samples at baseline, 5 h and 10 h during each of the 10 h sampling periods. Circulating LH concentrations were measured in duplicate at all times. The samples were divided
Results
into seven LH assays and in each assay, quadruplicate samples from six established LH serum pools were included as controls and the Basal hormone profile coefficients of variation (Table I) were computed using the method In women with PCOS, the mean (Ϯ SEM) basal concentration described by Rodbard (1974) . The corresponding mean dose concenof LH, 24.48 Ϯ 4.56 IU/l, was substantially higher than that trations and standard deviations of the six serum pools were also observed in the control group, 8.52 Ϯ 1.59 IU/l (Table II, calculated to generate the Baxter parameters (Baxter, 1980) as required Figure 1 ). In contrast, mean concentrations of FSH were similar by the Munro Program (Taylor, 1987) for the 'pulsar' algorithm (see in both groups. The pattern of LH release in PCOS revealed below). In a typical assay run, the complete LH data set for the whole study of one subject with PCOS and one control were included. significant increases in pulse amplitude and pulse frequency amplitude and LH pulse frequency for women with polycystic hormone (LH) and follicle-stimulating hormone (FSH) for women ovary syndrome (PCOS) and normal ovulatory women derived with polycystic ovary syndrome (PCOS) and normal ovulatory from the 'cluster' algorithm. The duration of GnRHa treatment was women before gonadotrophin-releasing hormone agonist (GnRHa) 14 weeks (arrow). treatment (0 wk of R x ), at 12 weeks of treatment (12 wk of R x ) and at 1, 2 and 4 weeks after discontinuing treatment (1, 2 and 4 wk post-R x ). The duration of GnRHa treatment was 14 weeks (arrow). A significant between-group difference at a particular time point is In PCOS, mean baseline concentrations of circulating androillustrated by a P value above the relevant pair of error bars.
gens, androstenedione and testosterone were significantly Significant within-group differences between time points are greater than those found in normal controls (Table II) ing concentrations of oestrone were increased compared to wk post-R x and 2 wk post-R x respectively) above the relevant error bars. † and ∆ indicate differences at P Ͻ 0.001 and P Ͻ 0.01 control subjects whereas differences in serum oestradiol failed respectively while letters without superscripts indicate P Ͻ 0.05. to achieve statistical significance between the two groups. Reversal of the normal oestrone:oestradiol ratio in our patients was consistent with that of previously reported studies (DeVane compared to those of normal ovulatory women. The mean et al., 1975; Rebar et al., 1976; Chang et al., 1982) . Mean pulse amplitude in women with PCOS was 14.41 Ϯ 2.58 IU/ serum concentrations of progesterone and dehydroepiandrol, which was substantially greater than in the control group, sterone sulphate did not differ between women with PCOS 4.03 Ϯ 0.58 IU/l. Measurements of amplitude varied widely and normal ovulatory women. in individual patients as values ranged from 9.20 IU/l to 21.82 IU/l. In contrast, the magnitude of LH pulses among normal Effects of GnRHa ovulatory women was relatively consistent (Figure 2) . The mean LH pulse frequency in women with PCOS, 8.20 Ϯ 0.58 Mean serum FSH concentrations in both groups decreased significantly in response to GnRHa, whereas serum LH concenpeaks/10 h, was greater than that found in normal ovulatory women, 6.50 Ϯ 0.34 peaks/10 h. While this difference was trations were significantly reduced in PCOS only (Figure 1) . While a suppressive effect of GnRHa on LH concentrations statistically significant, there was some overlap of individual values between the two groups.
in normal ovulatory women was not observed, values were similar to the reduced concentrations of women with PCOS so that frequent blood sampling from study subjects could be safely resumed 1, 2 and 4 weeks after discontinuing GnRHa after 12 weeks of GnRHa treatment. Uniformly, there were significant decreases in LH pulse amplitude and frequency in treatment. Accordingly, no blood samples were collected when GnRHa suppression was expected to be maximal at 14 weeks. women with PCOS and normal ovulatory women following 3 months of GnRHa administration (Figure 2 ). In PCOS, LH However, that circulating concentrations of LH and ovarian steroids and LH amplitude reached a nadir 1 week after pulses were characterized by a mean magnitude of 4.91 Ϯ 1.22 IU/l and a mean frequency of 4.20 Ϯ 0.92 peaks/10 h, both of withdrawal of treatment would reflect the effects of these 2 additional weeks of GnRHa suppression (see below). which were similar to corresponding values measured in the control group. Mean circulating concentrations of androsteneRecovery from GnRHa dione and oestradiol in both groups were significantly decreased by GnRHa (Figure 3 ). In addition, significant reduction of One week following discontinuation of GnRHa, serum concentrations of LH and FSH in both groups remained suppressed serum testosterone and oestrone were noted in women with PCOS. Significant decrements in mean serum testosterone in (Figure 1) compared to values at 12 weeks (i.e. 2 weeks before GnRHa was suspended). In contrast, the pattern of pulsatile normal ovulatory women were not observed, a pattern which persisted throughout the study. Serum progesterone concentra-LH secretion in PCOS revealed an immediate restoration of mean pulse frequency similar to that found during pre-treatment tions in both groups were decreased in response to GnRHa, whereas serum dehydroepiandrosterone sulphate concentraassessment (Figure 2 ). These LH pulses, however, were of small magnitude and were lower than the diminished amplitude tions remained unchanged (Figure 4) . Following 3 months of GnRHa suppression, there were no differences in gonadoobserved at 12 weeks (Figure 2 ). The control group also exhibited a return of pre-treatment LH pulse frequency which, trophin and steroid profiles between women with PCOS and the control group. As mentioned previously, GnRHa treatment interestingly, was not significantly different from the corresponding rate of pulsatile LH release in PCOS. Mean LH pulse was extended from 12 to 14 weeks to provide 2 extra weeks between the two groups. Correspondingly, changes in mean steroid hormone concentrations in both women with PCOS and normal ovulatory women began to reflect resumption of ovarian steroidogenesis during the second week of recovery (Figure 3 ). During this period, a modest but significant increment in the mean serum androstenedione concentration was detected in women with PCOS whereas subjects in the control group failed to demonstrate similar evidence of increased ovarian androstenedione production. The resultant increase in circulating androstenedione in PCOS was statistically different from the mean androstenedione value in normal ovulatory women (Figure 3 ). Unlike androstenedione, serum testosterone levels remained unchanged in both groups. In PCOS, increases of serum oestrone and oestradiol concentrations were not observed compared to values found during the first week of recovery. In the control group, serum oestrone was unaltered whereas oestradiol concentrations increased significantly to achieve pre-treatment values among some controls. Progesterone levels remained suppressed and similar in both groups (Figure 4) .
Four weeks following the cessation of GnRHa administration, mean FSH levels in both groups remained in the pretreatment range (Figure 1 ). In women with PCOS, there was a small increase in mean serum LH concentrations which did not achieve statistical significance. By comparison, the control group exhibited an increase of circulating LH which was significantly greater than that previously measured during recovery. In both groups, the mean LH pulse frequency was maintained at pre-treatment rates (Figure 2) . Examination of mean LH pulse amplitude in normal ovulatory women revealed a significant increase which was greater than the magnitude of LH pulses noted at 1 and 2 weeks after GnRHa withdrawal and which were comparable to baseline pre-treatment values. to GnRHa administration. The mean LH amplitude between the two groups was not significantly different. In both groups, a clear trend of increasing values of mean LH pulse amplitude, amplitudes were similar in the two groups. Representative LH which closely mirrored that of circulating LH, could be pulsatile patterns of a woman with PCOS and a normal demonstrated over the four-week recovery period (Figures 1, ovulatory woman are illustrated in Figure 5 . During this early 2). During this interval of study in PCOS women, mean serum recovery phase, mean steroid hormone concentrations in both androstenedione concentrations continued to increase but had groups were maximally suppressed (Figure 3) , a pattern similar not returned to baseline values. In normal ovulatory women, to that observed for LH pulse amplitude and mean circulating serum androstenedione concentrations remained unaltered, LH concentrations (Figures 1, 2) . The lack of ovarian steroid thereby increasing the difference between groups. Concomitsecretion in PCOS immediately following cessation of longantly, PCOS patients exhibited a significant increase in serum term GnRHa treatment was consistent with our previous testosterone concentrations, which essentially restored baseline published results (deZiegler et al., 1989) . values ( Figure 3 ). In contrast, normal ovulatory women failed to Two weeks after withdrawal of GnRHa, mean FSH concendemonstrate any change in serum testosterone concentrations, trations returned to pre-treatment values and remained similar which was a consistent finding throughout the study. Marked in both women with PCOS and normal ovulatory women increases in serum oestrone and oestradiol concentrations were (Figure 1 ). In PCOS, mean LH concentrations were still noted in both patients with PCOS and normal ovulatory suppressed from pre-treatment values. Mean LH pulse frewomen. These changes were reflective of significant ovarian quency in women with PCOS and normal ovulatory women follicular activity as serum progesterone concentrations also remained at pre-treatment values and were not different exhibited substantial increases at this time. Mean dehydroepianbetween the two groups (Figure 2) . In PCOS, a small increase drosterone sulphate concentrations were not altered throughout in LH pulse amplitude was noted which did not represent a significant change within the group nor a significant difference the entire course of study (Figure 4 ). Representative plots of serum luteinizing hormone (LH) concentrations at 10-min intervals for a 10 h duration before treatment (R x ), at 12 weeks of R x and at 1, 2 and 4 weeks post-R x in a woman with polycystic ovary syndrome (PCOS) and a normal ovulatory woman. Significant LH peaks detected by the 'cluster' algorithm are marked by asterisks (*).
Cluster versus pulsar algorithm release during this time. LH pulse frequency remained unaltered during the recovery period despite a return of oestrogen to Mean values of LH pulse amplitude derived from the pulsar pre-treatment levels. Our findings are contrary to those of algorithm ( Figure 6 ) closely resembled those from the cluster previous studies, which have indicated that increased LH pulse algorithm (Figure 2) . Within-and between-group changes in frequency in PCOS may be attributed to an association between mean LH pulse frequency rates during the course of study GnRH and oestrogen secretion. The ability to distinguish the were also similar, despite variations from the cluster algorithm effect of GnRH from that of gonadal steroid feedback on LH in the number of LH pulse peaks detected among individuals.
pulse frequency has been achieved in earlier reports utilizing Because the model of least fitted variance for the cluster GnRH-deficient models (Belchetz et al., 1978; Spratt et al. , algorithm was directly derived from the study data set, results 1987). In rhesus monkeys with hypothalamic lesions or men using this algorithm were considered more robust and were with idiopathic hypogonadotrophic hypogonadism, progressive referred to in the following discussion.
increases in the delivery rate of GnRH have been shown to induce increased LH pulse frequencies much like those of Discussion PCOS without apparent influence from gonadal steroid production. In the design of our study model, an effect of ovarian The results of this study have demonstrated that in women with steroid feedback was not evident. Our data, therefore, are PCOS and normal ovulatory women, return of gonadotrophin consistent with animal (Belchetz et al., 1978;  Clarke and secretion after cessation of long-term GnRHa treatment was Cummins, 1982; Levine and Ramirez, 1982) and limited characterized by an early restoration of LH pulse frequency human (Spratt et al., 1987) data that LH pulse frequency is followed by a gradual resumption of pulse amplitude. The primarily determined by hypothalamic GnRH activity. Howsuppressive effect of GnRHa on ovarian steroid secretion was ever, this does not preclude the well-recognized effect of substantial as significant decreases in circulating androsteneluteal-phase progesterone concentrations in slowing LH pulse dione, testosterone, oestrone and oestradiol were demonstrated frequency (Soules et al., 1984) and reducing basal LH concenin PCOS. Concentrations of androstenedione and oestradiol trations (Baird et al., 1977) . Indeed, the wider range in LH were also significantly suppressed in normal ovulatory women. pulse frequency rates observed at 4 weeks after discontinuing Clinically, the reduction in oestrogen concentrations was GnRHa was consistent with this effect in one patient with accompanied by the appearance of vasomotor instability among PCOS and two control subjects who demonstrated rising all subjects. The observation at 1 week after discontinuing progesterone concentrations and apparent ovulation. Taken GnRHa provided a critical window to contrast intrinsic GnRH together, the fact that there was no difference in LH pulse pulsatility, since circulating concentrations of gonadotrophins frequency between the two groups during the recovery period and ovarian steroids were maximally suppressed and equivalent (before ovulation and before full evolution of the chronic, in both groups. Notably, LH pulse frequency was not significaberrant hormone state pathognomonic of women with PCOS) antly different from their respective basal values and was would suggest that heightened LH pulse frequency observed not significantly different between the two groups. The rein women with PCOS was not due to a higher firing rate of establishment of baseline pre-treatment pulse frequency prior to GnRH/LH pulsatile secretion intrinsic to the hypothalamicrecovery of ovarian steroid production indicates that oestrogen feedback has minimal, if any, influence on the rate of LH pituitary unit but a consequence of prolonged anovulation and doses for the same treatment duration among women with endometriosis. It remained possible that LH pulses were ablated after 14 weeks of GnRHa treatment but frequent blood sampling during GnRHa suppression was only performed at 12 weeks, for reasons discussed earlier. From our own experience and that reported in the literature (Jaakkola et al., 1990; Cheung and Chang, 1995) , it is recognized that LH values measured by the newer monoclonal immunometric assays based on chromofocusing techniques are generally lower than values obtained by conventional radioimmunoassay. We have also observed less intra-and interassay variations. Accordingly, the LH signal-to-noise ratio and the number of LH peaks identified by pulse detection algorithms could differ from that based on radioimmunoassay. Although radioimmunoassay was in fact used in the study, comparison was made specifically within each group and between the two groups using the same LH assay method. It was not the intention of the study to compare LH pulsatility using different assay techniques. With respect to pulse detection algorithm, interpretation of our data was unchanged whether the cluster or pulsar algorithm was used for comparison. In contrast to LH pulse frequency, detectable increases in pulse amplitude in PCOS were temporally related to progressive increases in serum oestrone and oestradiol concentrations. These results are consistent with the observation that increased exposure of pituitary gonadotrophs to oestrogen is associated with amplified LH responses to administration of GnRH (Jaffe and Keye, 1974; Shaw et al., 1975; Wang et al., 1976; Baird et al., 1977) . That LH pulse amplitude in PCOS had not returned to pre-treatment values by the end of recovery might have been due to the limited duration of study following discontinuation of GnRHa. It has been suggested that, in PCOS, increased LH pulse amplitude may be the result Figure 6 . Mean values Ϯ SEM of luteinizing hormone (LH) pulse of prolonged exposure to chronic oestrogen secretion or a amplitude and LH pulse frequency for women with polycystic manifestation of self-priming by GnRH or both (Rebar et al., ovary syndrome (PCOS) and normal ovulatory women derived Hoff et al., 1979) . Failure to achieve a sufficient duration from the 'pulsar' algorithm. The duration of GnRHa treatment was of either effect could account for the diminished pulse ampli-14 weeks (arrow). tude in PCOS. These same considerations may also apply to the recovery of circulating LH concentrations in PCOS which lack of cyclical exposure to progesterone. In this regard, extending assessment of pulsatile LH secretion beyond 4 weeks remained below baseline levels measured prior to the initiation of GnRHa treatment. By comparison, the group of normal after discontinuing GnRHa may provide valuable information, especially among anovulatory women with PCOS.
ovulatory women exhibited complete recovery of basal serum LH concentrations as well as LH pulse amplitude at the end It is interesting to note that LH pulsatility was still detectable, albeit at markedly lower frequency and amplitude, during of the study. The pattern of gonadotrophin secretion during recovery from GnRHa treatment despite significant suppression of circulating concentrations of LH and ovarian steroids. This is in contrast GnRHa suppression also permitted assessment of ovarian stimulation by endogenous LH and FSH. In particular in to a previous report which showed that pulsatile secretory pattern of both LH and free α-subunit were abolished by a PCOS, ovarian androgen responses to the resumption of LH secretion revealed significant increases of serum androstenesingle depot injection of the GnRHa, D-Trp using a nonGaussian model for time series to detect pulses (Couzinet dione and testosterone whereas in the control group, no incremental changes were observed. These findings suggested et al., 1991) . Potential factors that might account for the discrepancy include the dose, duration and type of GnRHa that androgen-producing tissues of patients with PCOS were more responsive to LH stimulation than those of normal treatment, between-subject variability in response to GnRHa suppression and recovery, hormone assay techniques and ovulatory women since throughout recovery, basal serum LH concentrations, LH pulse frequency and LH pulse amplitude criteria used to detect LH peaks. The D-His dose of 2 µg/kg selected in the study was designed to adjust for body weights were similar between the two groups. Our data support the results of in-vitro studies performed on stromal and thecal and was based on a pilot study in which adequate pituitaryovarian suppression could be demonstrated using comparable tissues from women with PCOS in which androstenedione and
